Percutaneous coronary intervention (PCI) is the predominant revascularization strategy in patients with acute coronary syndromes (ACS), and intracoronary stents have improved procedural success and decreased rates of angiographic restenosis compared with conventional balloon angioplasty (1) . Although stents have led to improvements in target lesion revascularization rates, they have also been associated with stent thrombosis, a highly morbid complication (2) .
The incidence of stent thrombosis is significantly reduced by the administration of dual antiplatelet therapy (DAPT), implicating platelet activation as an important mediator of this complication (3) . Efforts to reduce stent thrombosis have therefore focused on minimizing the discontinuation of DAPT and identifying those patients who have a poor response to thienopyridine therapy (4) .
There have been relatively few contemporary studies examining oral anticoagulation and its role in the prevention of thrombotic complications of ACS and stent thrombosis (3, 5) . Rivaroxaban is an oral anticoagulant that directly and selectively inhibits factor Xa, interrupts the coagulation cascade, and thereby reduces the formation of thrombin. Inhibition of factor Xa is an attractive mechanistic target because thrombin generated on the surface of the activated platelet induces further platelet activation through the thrombin receptor (protease-activated receptor 1) to form a local positive-feedback loop (6) . Indeed, rivaroxaban successfully inhibited high-shear-induced stent thrombosis in a porcine ex vivo model; when combined with DAPT, rivaroxaban reduced stent thrombus weight to a nearly undetectable limit of 2% (vs. 21% with DAPT alone) (7) . It was therefore hypothesized that rivaroxaban administration is associated with a reduction in stent thrombosis, and this hypothesis was prospectively tested among patients with ACS randomized in the ATLAS-ACS 2 TIMI 51 (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary SyndromedThrombolysis in Myocardial Infarction 51) trial.
Methods
The ATLAS-ACS 2 TIMI 51 trial (8, 9) enrolled patients (!18 years of age) who presented with symptoms suggestive of ACS. The present analysis was restricted to patients with a history of stent placement, including those receiving stents before study enrollment and those who received stents during the index PCI. Enrollment occurred within 7 days (median: 4.3 days) of hospital admission, and patients were randomly assigned in a 1:1:1 fashion to twice-daily administration of either 2.5 mg or 5.0 mg of rivaroxaban or placebo, with a maximum follow-up of 31 months.
All patients were to receive standard medical therapy at the enrolling physician's discretion at a dose recommended in either national or local guidelines. Stratum 1 was defined as those patients whom the enrolling physician chose to treat with aspirin alone, and stratum 2 was defined as those patients treated with aspirin plus a thienopyridine (8, 9) .
The primary efficacy endpoint of the ATLAS-ACS 2 TIMI 51 trial was a composite of death from cardiovascular causes, myocardial infarction, and stroke (ischemic, hemorrhagic, and stroke of uncertain cause) (8) . Complete definitions of the endpoints have been reported previously (9) . Stent thrombosis was a predefined endpoint reported by the enrolling physician and was independently adjudicated based upon the Academic Research Consortium (ARC) designations of definite, probable, or possible (2) . Statistical analysis. Efficacy analyses were performed using a modified intention-to-treat (mITT) approach, which has been described previously (8, 9) . Sensitivity efficacy analyses were conducted with the use of an ITT approach, which included all patients and all endpoint events occurring after randomization until the global treatment end date.
Hazard ratios (HR) with 2-sided 95% confidence intervals (CI) were used to compare the study groups. Rates of the endpoints were expressed as Kaplan-Meier estimates through 24 months. Results were examined according to major subgroups for general consistency of treatment effect, and interaction testing was performed.
Results
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Aside from a slightly greater age among rivaroxaban patients, there was no difference in baseline characteristics between stented patients randomly assigned to rivaroxaban versus placebo (Table 1) .
ARC definite or probable (Fig. 1A) and ARC definite, probable, or possible (Fig. 1B ) stent thrombosis were significantly reduced in the pooled group of all patients treated with rivaroxaban (both 2.5 mg and 5 mg twice-daily doses combined). There was also a reduction in definite stent thrombosis among all patients treated with rivaroxaban versus placebo (Fig. 2) . This reduction achieved statistical significance when limited to those patients with ARC-defined definite or probable stent thrombosis in both the pooled (HR: 0.65; p ¼ 0.017) and the rivaroxaban 2.5 mg twice-daily (HR: 0.61; p ¼ 0.023) groups (Fig. 3) .
The reduction in stent thrombosis with rivaroxaban (pooled doses) was consistent across a number of subgroups (Online Tables 1 and 2 ). There was homogeneity (p for interaction ¼ 0.95) in the magnitude of the reduction in stent thrombosis among patients in whom a bare-metal stent was implanted (HR: 0.69; p ¼ 0.042) and in whom a drug-eluting stent was implanted (HR: 0.68; p ¼ 0.170). No significant reduction was noted in the small subgroup of patients who received a stent before randomization (Online Table 3 ). In a landmark analysis, the magnitude of the treatment effect associated with rivaroxaban administration was fairly homogenous over time. Within 30 days of randomization, definite, probable, or possible stent thrombosis tended to be reduced in the pooled rivaroxaban group (HR: 0.65; 95% CI: 0.41 to 1.03; mITT and ITT p ¼ 0.067). There was a comparable magnitude of reduction in the HR associated with rivaroxaban administration from 30 days to 2 years after enrollment (HR: 0.72; 95% CI: 0.46 to 1.13; mITT p ¼ 0.154; ITT p ¼ 0.081).
Among patients who received both aspirin and a thienopyridine (stratum 2), the benefit of rivaroxaban emerged during the period of active treatment with DAPT before any discontinuation of the thienopyridine (HR: 0.68; 95% CI: 0.50 to 0.92) in the combined rivaroxaban group versus placebo. There was a mortality reduction among those patients in stratum 2 treated with twice-daily rivaroxaban 2.5 mg (HR: 0.56; 95% CI: 0.35 to 0.89; mITT p ¼ 0.014; ITT p ¼ 0.039) (Fig. 4) but not twice-daily rivaroxaban 5 mg.
Discussion
Rivaroxaban administration is associated with a reduction in stent thrombosis defined using a variety of ARC definitions. The benefit of rivaroxaban when added to DAPT emerged early and was preserved over time. A priori it may have been hypothesized that rivaroxaban would reduce the risk of stent thrombosis following cessation of thienopyridine therapy. However, a key finding from the present study was that rivaroxaban reduced the risk of stent thrombosis during the period of active DAPT. It should be noted that the oral anticoagulant apixaban demonstrated a similar reduction in stent thrombosis in the APPRAISE-2 (Apixaban for Prevention of Acute Ischemic Events 2) study, but this reduction did not reach statistical significance because the study was stopped prematurely due to an increase in major bleeding events (10) . A similar reduction in stent thrombosis was not reported with the thrombin receptor antagonist vorapaxar (11) .
The underlying mechanism by which rivaroxaban reduces stent thrombosis when added to DAPT in animal and human studies is not known. It is not known whether the observed reduction in stent thrombosis in this study was mediated by a reduction in thrombin generation, which in turn directly mediates stent thrombosis, or if the reduction in stent thrombosis was mediated by a reduction in the stimulation of platelet aggregation because thrombin is a potent stimulant of platelets.
Conclusions
The factor Xa inhibitor rivaroxaban significantly reduced stent thrombosis in patients with ACS. The benefit emerged during the period of DAPT with aspirin plus a thienopyridine. The results of this analysis highlight the potential additive benefit of inhibiting thrombin generation over DAPT alone among stented patients.
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